Magnetite ZnO Composite Nanoparticles
Phase 1Small molecule
Magnetite ZnO Composite Nanoparticles is one of 37 small molecule programs targeting Effectiveness. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
76 competitors in Effectiveness
#DrugCompanyPhaseTrials
1Kesimpta
NovartisPhase 3
Mounjaro
Eli LillyPhase 3
Actos
TakedaPhase 3
Elucirem
GGuerbet
Phase 3
Nicotine Free Cigarettes
PfizerPhase 3
Lidocain
BayerPhase 3
Botulinum Toxin a
GSKPhase 3
Pneumococcal Conjugate Vaccine
NovartisPhase 3
Haldol
DDePuy Orthopaedics
Phase 2
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Effectiveness1 trial
Effectiveness of Topical Magnetite Zinc Oxide Composite Nanoparticles in the Management of Oral Potentially Malignant Lesions
Recruiting·—·Phase 1·NCT06271564·20 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- AAin Shams University